Laboratory Medicine Program

Chronic Myelogenous Leukemia: BCR/ABL1 t(9;22)

Clinical Decription:
A chromosomal translocation that results in the fusion of the BCR and ABL1 genes can occur in various hematologic malignancies including chronic myelogenous leukemia (CML). Patients with the BCR/ABL1 genes fusion are sensitive to treatment with tyrosine kinase inhibitors. Quantitative reverse transcriptase PCR is performed to detect the p210 and p190 BCR-ABL1 fusion variants at diagnosis and monitor treatment response known as minimal residual disease monitoring.

Method: PCR - Real-Time Quantitative

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Peripheral Blood/Bone Marrow/Extracted RNA
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Test will be billed to the referring hospital, laboratory, physician or medical group. See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227